Trodelvy

Former Immunomedics CFO pleads guilty to securities fraud over Trodelvy tip
Former Immunomedics CFO pleads guilty to securities fraud over Trodelvy tip
Fierce Biotech
Immunomedics
Usama Malik
insider trading
legal
Trodelvy
Flag link:
Gilead reports positive data from urothelial cancer therapy trial cohorts
Gilead reports positive data from urothelial cancer therapy trial cohorts
Clinical Trials Arena
Gilead Sciences
Trodelvy
metastatic urothelial cancer
clinical trials
Flag link:
Gilead's Trodelvy snags vital breast cancer nod
Gilead's Trodelvy snags vital breast cancer nod
Fierce Pharma
Gilead Sciences
FDA
Trodelvy
breast cancer
HR-positive HER-negative breast cancer
Flag link:
Gilead Sciences to provide Trodelvy for Strata PATH trial
Gilead Sciences to provide Trodelvy for Strata PATH trial
Clinical Trials Arena
Gilead Sciences
Strata Oncology
Trodelvy
clinical trials
Flag link:
5 FDA decisions to watch in the first quarter
5 FDA decisions to watch in the first quarter
BioPharma Dive
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
Flag link:
After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review
After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review
Fierce Pharma
Gilead Sciences
breast cancer
Trodelvy
ESMO
FDA
priority review
Flag link:
ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival showing
ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival showing
Fierce Pharma
Gilead Sciences
Trodelvy
ESMO
HR-positive HER-negative breast cancer
breast cancer
Flag link:
After Trodelvy's approval in China, Gilead strikes $455M deal with Everest for Asian rights
After Trodelvy's approval in China, Gilead strikes $455M deal with Everest for Asian rights
Fierce Pharma
Gilead Sciences
Immunomedics
Trodelvy
Everest Medicines
Flag link:
ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt
ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt
Fierce Pharma
Gilead Sciences
Trodelvy
breast cancer
ASCO 2022
Flag link:
3 cancer drug studies to watch at next month’s ASCO meeting
3 cancer drug studies to watch at next month’s ASCO meeting
BioPharma Dive
ASCO 2022
AstraZeneca
Enhertu
Gilead Sciences
Trodelvy
Roche
tiragolumab
cancer
Flag link:
Gilead’s Covid-19 treatment Veklury props up first quarter gains amid $2.7B Trodelvy writedown
Gilead’s Covid-19 treatment Veklury props up first quarter gains amid $2.7B Trodelvy writedown
Endpoints
Gilead Sciences
Veklury
remdesivir
earnings
Trodelvy
Flag link:
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030
Fierce Pharma
Gilead Sciences
oncology
cancer
Yescarta
Trodelvy
Flag link:
That key Gilead breast cancer readout? Try 2024, and don't get your hopes up: analyst
That key Gilead breast cancer readout? Try 2024, and don't get your hopes up: analyst
Fierce Pharma
Gilead Sciences
Trodelvy
breast cancer
Flag link:
Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters
Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters
Fierce Pharma
Gilead Sciences
Immunomedics
Trodelvy
layoffs
Flag link:
Gilead says breast cancer drug succeeded in key study, but offers few details
Gilead says breast cancer drug succeeded in key study, but offers few details
BioPharma Dive
Gilead Sciences
Trodelvy
clinical trials
M&A
breast cancer
Flag link:
10 clinical trials to watch in the first half of 2022
10 clinical trials to watch in the first half of 2022
BioPharma Dive
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Flag link:
AZ, Daiichi take aim at Gilead in triple-negative breast cancer
AZ, Daiichi take aim at Gilead in triple-negative breast cancer
Pharmaforum
AstraZeneca
Daiichi Sankyo
Gilead Sciences
Trodelvy
triple negative breast cancer
Dato-DXd
Flag link:
Gilead, Merck to study combination therapy for breast cancer
Gilead, Merck to study combination therapy for breast cancer
Pharmaceutical Business Review
Gilead Sciences
Merck
Trodelvy
Keytruda
triple negative breast cancer
Flag link:
Oncology the focus for big pharma catalysts
Oncology the focus for big pharma catalysts
EP Vantage
Big Pharma
cancer
oncology
Merck
Keytruda
AbbVie
Vraylar
Gilead Sciences
Trodelvy
Sanofi
Sarclisa
Novartis
ligelizumab
Flag link:
Gilead keeps pushing trove of Trodelvy data as it seeks to become new standard of care in TNBC
Gilead keeps pushing trove of Trodelvy data as it seeks to become new standard of care in TNBC
Endpoints
ESMO
Gilead Sciences
Trodelvy
triple negative breast cancer
Flag link:

Pages